Search clinical trials for: GLIM

Total 421 results

Peking Union Medical College Hospital
Chinese Academy of Sciences

Unknown

Response of Gut Microbiota in Type 2 Diabetes to Hypoglycemic Agents

Type2 Diabetes Mellitus

China
Carl Zeiss Meditec AG

Unknown

Use of the VisuMax Femtosecond Laser Lenticule Removal Procedure for the Correction of Hyperopia (V1601CI)

Hypermetropia

China, Czechia, France, Germany, India, United Kingdom
University of Jordan

Completed

Dosage Reduction and Acute Glycemic Complications in People With Type 2 Diabetes Who Fast During Ramadan

Diabetes Mellitus, Type 2

Jordan
University of Leicester
University Hospital Birmingham

Completed

Canagliflozin (Invokana™) vs. Standard Dual Therapy Regimen for T2DM During Ramadan (Can Do)

Diabetes Mellitus, Type 2

United Kingdom
Haukeland University Hospital

Unknown

Switching From Insulin to Sulfonylurea in Diabetes Associated With Variants in MODY Genes (SUtoChildT1D)

Insulin-dependent Diabetes Mellitus | Maturity-Onset Diabetes of the Young, Type 3 | Maturity Onset Diabetes of the Young, Type 1 | Childhood Diabetes Mellitus

Norway
Osijek University Hospital
Josip Juraj Strossmayer University of Osijek

Completed

An Observer Rating Scale of Facial Expression Can Predict Dreaming in Propofol Anesthesia

Drug Effect | Anesthesia | Propofol
Boehringer Ingelheim
Eli Lilly and Company

Completed

CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Taiwan, Philippines, Australia, Hong Kong, Korea, Republic of, Canada, Italy, Malaysia, United Kingdom, Mexico, Greece, Spain, Netherlands, Switzerland, Israel, Portugal, Germany, Finland, Norway, Romania, Sweden, Serbia and more
Kevin Watt

Completed

Pharmacokinetics of Micafungin in Children on Extracorporeal Membrane Oxygenation

Invasive Candidiasis

United States
Eli Lilly and Company

Terminated

A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM) (IMPERIUM)

Diabetes Mellitus, Type 2

United States, Puerto Rico, Germany, United Kingdom, Austria
Eli Lilly and Company

Completed

A Study Comparing the Effects and Safety of Dulaglutide With Glimepiride in Type 2 Diabetes Mellitus (AWARD-CHN1)

Type 2 Diabetes Mellitus

China, Korea, Republic of, Taiwan
AdventHealth

Completed

Detection of SLN in Patients With Endometrial Cancer Undergoing Robotic Assisted Staging: Comparison of ISB and ICG

Endometrial Cancer

United States
AstraZeneca

Completed

Foxiga Korea Local Phase 4 Study (BEYOND)

Diabetes Mellitus, Type 2

Korea, Republic of
Guy's and St Thomas' NHS Foundation Trust
King's College London; City, University of London

Completed

A Study Comparing Two Monofocal, Aspheric, Hydrophobic Acrylic Intraocular Lenses: the Alcon CLAREON® and the Abbott Medical Optics PCB00

Patient Satisfaction | Cataract Extraction | Cataract Surgery | Phacoemulsification | Intraocular Lens Implant | Patient Related Outcome Measures | Glistenings | Hydrophobic Acrylic | Light Scatter

United Kingdom
Kansai Electric Power Hospital
Saiseikai Noe Hospital Osaka

Completed

Dietary Impacts on Glucose-lowering Effects of Sitagliptin in Type 2 Diabetes (DIET)

Diabetes Mellitus, Type 2

Japan
University Hospital, Gentofte, Copenhagen

Completed

The Effect of GIP and GLP-1 on Insulin and Glucagon Secretion in Patients With HNF1A-diabetes Treated With or Without Sulphonylurea (HNF1A-Clamp)

Maturity-Onset Diabetes of the Young, Type 3

Denmark
Universidade Ibirapuera

Completed

Botulinum Toxin in the Treatment of Gingival Smile

Smiling

Brazil
Astellas Pharma Europe B.V.
World Health Information Science Consultants, LLC

Completed

Short and Long-term Safety of Micafungin and Other Parenteral Antifungal Agents (MYCOS)

Systemic Fungal Infections

United States
Yonsei University

Completed

Clinical Outcomes of Small-incision Lenticule Extraction (SMILE) Using Vector Planning Method.

Myopic Astigmatism

Korea, Republic of
Astellas Pharma Inc

Completed

A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Sulfonylurea in Type 2 Diabetic Patients

Type 2 Diabetes Mellitus

Japan
Astellas Pharma Global Development, Inc.
IRCCS, Ospedale Pediatrico Bambino Gesu

Completed

Determination of Levels of Micafungin in Neonates Suffering From Systemic Candidiasis and/or Candida Meningitis

Candidiasis, Systemic | Candida Meningitis

Italy
Merck Sharp & Dohme LLC
Pfizer

Completed

Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)

Type 2 Diabetes Mellitus
Amanda D. Spear, CCRC

Completed

Evaluation of the Efficacy of Restylane Silk in the Treatment of Cheek Fold (Radial Smile Lines)

Smile Lines
Astellas Pharma S.A.S.

Completed

Use of Micafungin (Mycamine®) as Antifungal Prophylaxis in Haematology and Onco-haematology (OLYMPE)

Antifungal Prophylaxis | Haemopathy

France
AstraZeneca

Completed

Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With Sulphonylurea

Type 2 Diabetes Mellitus | Inadequate Glycaemic Control

Germany, Slovakia, Czechia, Hungary, Poland
Hannover Medical School
Boehringer Ingelheim

Terminated

SGLT2 Inhibition and Left Ventricular Mass (EMPATROPHY)

Diabetes Mellitus Type 2

Germany
Astellas Pharma Inc

Completed

Liver Transplant European Study Into the Prevention of Fungal Infection (TENPIN)

Liver Transplantation | Mycoses

Belgium, France, Italy, Spain, Ireland, Germany, Portugal, Saudi Arabia, Austria, United Kingdom, Russian Federation, Hungary, Sweden, Romania
Intarcia Therapeutics

Terminated

Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on Metformin

Diabetes Mellitus, Type 2

United States, Canada
GWT-TUD GmbH

Terminated

Risk of Nocturnal Hypoglycemia and Arrhythmias With Sitagliptin Versus Glimepiride in Patients With Type 2 Diabetes

Diabetes Mellitus Type 2

Germany
Centre Hospitalier Universitaire de Nīmes

Completed

Pharmacokinetic Study on Echinocandins for Patients With Septic Shock Following Secondary Peritonitis

Septic Shock | Peritonitis

France, Australia
Astellas Pharma China, Inc.

Terminated

Post Marketing Study to Evaluate the Safety and Efficacy of Micafungin Against Fungal Infections Caused by Candida Spp or Aspergillus Spp

Candidiasis | Aspergillosis

China
Alcon, a Novartis Company

Terminated

Comparison of Topography Guided LASIK With WaveLight® EX500 to SMILE With Zeiss VisuMax

Astigmatism | Myopia

France
University Hospital, Limoges

Completed

Pharmacokinetics of Micafungin in Patients of Intensive Care Units (MI-K)

Invasive Candidiasis

France
Astellas Pharma China, Inc.

Terminated

A Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or Candidemia

Candidemia | Candidiasis

China
Astellas Pharma China, Inc.

Terminated

Post Marketing Study to Evaluate the Efficacy and Safety of Micafungin Treatment on Invasive Aspergillosis

Invasive Aspergillosis

China
Merck Sharp & Dohme LLC
Pfizer

Completed

A Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Participants With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Monotherapy (MK-8835-012)

Type 2 Diabetes Mellitus
Astellas Pharma Singapore Pte. Ltd.

Completed

Non-interventional Study for Prevention and Treatment of Fungal Infections in Paediatric Patients in Asia/Oceania - ERADICATE Study

Invasive Fungal Infections

Hong Kong, Korea, Republic of, Singapore, Taiwan, Thailand
Hannover Medical School

Terminated

Empagliflozin Reduces Progression of Diabetic Retinopathy in Patients With High Risk of Diabetic Macular Edema

Diabetes Mellitus, Type II

Germany
Samsung Medical Center
Novartis

Completed

The Effect of Vildagliptin Based Treatment Versus Sulfonylurea on Glycemic Variability, Oxidative Stress, GLP-1, and Endothelial Function in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

Korea, Republic of
Merck Sharp & Dohme LLC
Pfizer

Completed

Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC
Pfizer

Completed

Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC
Pfizer

Completed

Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Study to Evaluate the Safety and Efficacy of the Addition of Omarigliptin (MK-3102) Compared With the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)

Type 2 Diabetes
Merck Sharp & Dohme LLC

Completed

Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Study to Assess the Safety and Efficacy of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control (MK-3102-011)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC
Pfizer

Completed

A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Terminated

A Study to Evaluate the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus for Whom Metformin is Inappropriate (MK-3102-027)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Study of the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016)

Type 2 Diabetes Mellitus
Novo Nordisk A/S

Terminated

Effect of Inhaled Pre-prandial Human Insulin on Blood Glucose Control in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States
Merck Sharp & Dohme LLC

Terminated

A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266)

Type 2 Diabetes Mellitus

3

Subscribe